Flexion Therapeutics Stock News

Flexion Therapeutics, Inc. (NASDAQ:FLXN) was the recipient of a large growth in short interest during the month of October. As of October 29th, there was short interest totalling 2,160,000 shares, a growth of 15.5% from the October 14th total of 1,870,000 shares. Approximately 5.1% of the companys shares are short sold. Based on an average []

Northland Securities reiterated their market perform rating on shares of Flexion Therapeutics (NASDAQ:FLXN) in a research report sent to investors on Friday morning, The Fly reports. Several other equities analysts have also recently issued reports on the stock. Credit Suisse Group cut shares of Flexion Therapeutics from an outperform rating to a neutral rating and []

-- Adds highly complementary ZILRETTA ® to Pacira commercial offering -- -- Combined portfolio offers end-to-end non-opioid solutions along the pain pathway --

Flexion Therapeutics Inc. (NASDAQ:FLXN)s traded shares stood at 1.45 million during the latest session, with the companys beta value hitting 1.56. At the last check today, the stocks price was $9.17, to imply an increase of 0.33% or $0.03 in intraday trading. The FLXN shares 52-week high remains $13.66, putting it -48.96% down since that Flexion Therapeutics Inc. (NASDAQ: FLXN) Stocks Fall -20.80% YTD; What Next For It? Read More »

On Flexion's (FLXN) third-quarter earnings call, investor focus will be on its updates on earnings and revenues and the upcoming merger with Pacira whereby the latter will acquire the former.

Flexion Therapeutics recently announced that they have agreed to be acquired by Pacira BioSciences for $8.50 a share bid with the potential for an extra $8 from CVR. I provide a brief background on Pa

NEW YORK, Oct. 11, 2021 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Flexion Therapeutics, Inc. (NASDAQ: FLXN) and its board of directors concerning the pro

New York, New York--(Newsfile Corp. - October 11, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All Persons or Entities who purchased Flexion Therapeutics, Inc. (NASDAQ:

MILWAUKEE, Oct. 11, 2021 /PRNewswire/ -- Ademi LLP is investigating Flexion (Nasdaq: FLXN), for possible breaches of fiduciary duty and other violations of law in its transaction with Pacira. Click he

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Flexion Therapeutics, Inc. (NASDAQ: FLXN) to Pacira BioSciences, Inc. for $8.50 per

The stock price of Flexion Therapeutics Inc (NASDAQ: FLXN) increased by over 65% pre-market today. This is why it happened.

Tampa, Fla.-based Pacira BioSciences Inc. PCRX, -1.34% said Monday it is acquiring Flexion Therapeutics Inc. FLXN, +2.30% , based in Burlington, Mass.

-- Adds highly complementary ZILRETTA® to Pacira commercial offering -- -- Combined portfolio offers end-to-end non-opioid solutions along the pain pathway --

BURLINGTON, Mass., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to three new employees consisting of 6,315 restricted stock units

BURLINGTON, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in a